Ingredient	Quantity, mg/ml oral solution			
F2: oral solution (pH = 4 ± 1)				
risperidone	0.5			
tartaric acid	7.5			
benzoic acid	2			
Cherry flavour 1	0.25			
Cherry flavour 2	0.5			
sodium saccharin	1			
sodium hydroxide	q.s. ad $pH = 4 \pm 1$			
purified water	q.s. ad 1 ml			
F3: ora	solution (pH = 3)			
risperidone	0.5			
tartaric acid	7.5			
sodium chloride	5			
sodium saecharin	1			
sodium bydroxide	q.s. ad $pH = 3$			
purified water	q.s. ad 1 ml			
F4: ora	solution (pH = 5)			
risperidone	0.5			
tartaric acid	7.5			
sodium chloride	5			
sodium saccharin	1			
sodium hydroxide	q.s. ad $pH = 5$			
purified water	q.s. ad 1 ml			
F5: ora	solution (pH = 3)			
risperidone	1			
tartaric acid	7.5			
benzoic acid	2			
sodium hydroxide	ca. 1 (q.s. ad $pH = 3$)			
parified water	q.s. ad 1 ml			
F6 parente	ral solution (pH = 5)			
risperidone	2			
tartaric acid	7.5			
sodium chloride	5			
sodium hydroxide	ca. 3.75 (q.s. ad pH = 5)			
water for injection	q.s. ad 1 ml			

EXAMPLE 2

The tables hereinbelow summarize the risperidone concentrations measured after a particular storage time of the composition at a particular temperature, expressed as the percentage of the initial risperidone concentration.

		Fl	F2
4° C.	12 months	98.2	
25° C.	1 month	100.4	101.1
	3 months	102.1	99.1
	6 months	100.9	•
	9 months	99.5	
	12 mouths	98.7	
30° C.	3 months	102.1	98.8
	6 months	100.3	
	12 months	98.9	
40° C.	1 month	102,1	101.1
	3 months	100.9	99.4
	6 months	100.5	
	12 months	98.3	
60° C.	1 month	100.1	100.3

TABLE 2

		F3	F4
80° C. 5 days 17 days 4 weeks	5 days	97.9	99.0
		96.7	96.6
		86.2	87.6

The data in the tables indicate that compositions F1-F4 satisfy the criteria as set forth hereinbefore to qualify as a "physicochemically stable" composition.

We claim:

- 1. An aqueous solution suitable for oral and parenteral administration comprising water, risperidone or a pharmaceutically acceptable acid addition salt thereof, characterized in that said solution comprises a buffer to maintain the pH in the range of 2 to 6 and is essentially free of sorbitol.
- 2. A solution according to claim 1 wherein said pH range is obtained with a tartaric acid /sodium hydroxide buffer.
- 3. A solution according to claim 1 wherein the amount of risperidone ranges from 0.01% to 1% by weight based on the total volume of the solution.
 - 4. A solution according to claim 1 having a pH ranging from 3 to 4 which is suitable for oral administration.
 - A solution according to claim 4 further comprising benzoic acid as a preservative.
 - 6. A solution according to claim 5 containing
 - (a) 1 mg/ml risperidone;
 - (b) 2 mg/ml benzoic acid;
 - (c) 7.5 mg/ml tartaric acid and sufficient sodium hydroxide to adjust the pH in the range from 3 to 4; and
 - (d) water q.s. ad 1 ml.
 - 7. A solution according to claim 6 further comprising one or more members selected from the group consisting of sweetening agents and flavouring substances.
 - 8. A solution according to claim 1 having a pH ranging from 5 to 6 which is suitable for parenteral administration.
 - 9. A solution according to claim 4 further comprising sodium chloride as an isotonizing agent.
 - 10. A solution according to claim 9 containing
 - (a) 1 mg/ml risperidone;
 - (b) 5 mg/ml sodium chloride;
 - (c) 7.5 mg/ml tartaric acid and sufficient sodium hydroxide to adjust the pH in the range from 5 to 6; and
 - (d) water q.s. ad 1 ml.

45

50

- A process of preparing a solution according to claim
 comprising the steps of
 - (a) adding the acid component of the buffer and the active ingredient risperidone to an amount of water,
 - (b) stirring the mixture until complete dissolution and cooling the solution to room temperature,
- (c) adjusting the pH with the base component of the buffer,and
- (d) further diluting the solution with water to the required end-volume.
- 12. A process according to claim 11 for preparing an oral solution as defined in claim 5 wherein step (a) is preceded55 by the steps of:
 - (a) dissolving the preservative in an amount of heated water, and
 - (b) diluting the solution with about an equal amount of
 - 13. A process according to claim 11 for preparing an parenteral solution as defined in claim 9 wherein step (d) is preceded immediately by the step of rendering the solution about isotonic by the addition of an appropriate amount of isotonizing agent, and is followed by autoclaving.

* * * * *